Individual research recommendation details

Recommendation ID

CG186/5

Question

Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

Any explanatory notes
(if applicable)

Despite considerable success with agents that substantially reduce relapse frequency in the initial inflammatory, relapsing–remitting phase, over half of people eventually develop non-relapsing, secondary progressive MS 1 to 2 decades after the onset of relapsing–remitting MS. While a variety of symptomatic treatments is available, progression in secondary progressive MS is currently intractable, and immunomodulatory strategies used for relapsing–remitting MS have not proven effective when extended into secondary progressive MS (for example, beta interferon). Direct neuroprotection strategies (for example tetrahydrocannabinol) have also been ineffective. The critical and as yet unmet challenge therefore is to find effective and well-tolerated treatments for secondary progressive MS.

Source guidance details

Comes from guidance

Multiple sclerosis in adults: management

Number

CG186

Date issued

October 2014

Other details